Khurram Jamil sold $262k of GALT
Chief Medical Officer at GALECTIN THERAPEUTICS INC. 52,037 shares at an average of $5.04, traded Jun 26, 2026, filed Jun 30, 2026.
Score components
- +15RoleOfficer
- +13Trade size$262k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001133416-26-000059, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | MOption exercise Common Stock10b5-1 | +2,037 | $2.20 | $4,481 | 2,037 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock10b5-1 | -2,037 | $5.00 | $10k | 0 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Common Stock10b5-1 | +2,533 | $2.50 | $6,333 | 2,533 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock10b5-1 | -2,533 | $5.00 | $13k | 0 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +47,467 | $2.50 | $119k | 47,467 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -47,467 | $5.04 | $239k | 0 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Stock option (right to buy)derivative10b5-1 | -2,037 | $0.00 | $0 | 100,000 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,533 | $0.00 | $0 | 47,467 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -47,467 | $0.00 | $0 | 0 | Jun 30, 2026 |
Related signals
Other insiders at GALECTIN THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | GALECTIN THERAPEUTICS INC | Harold H. Shlevin director | $151k 30,000 shares | -211% | |
| 8Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $24k 7,557 shares | -100% | |
| 0Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $1,761 568 shares | -100% | |
| 23Weak | GALTbuy GALECTIN THERAPEUTICS INC | Kary Eldred director | $810 300 shares | +0% | |
| 35Weak | GALECTIN THERAPEUTICS INC | Jack W Callicutt Chief Financial Officer | $233k 60,000 shares | -89% | |
| 28Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $232k 60,000 shares | -100% | |
| 19Weak | GALECTIN THERAPEUTICS INC | Joel Lewis President and CEO | $321k 84,000 shares | -9% | |
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $33k 8,125 shares | -100% | |
| 16Weak | GALECTIN THERAPEUTICS INC | Kary Eldred director | $2,611 700 shares | +1% | |
| 31Weak | GALECTIN THERAPEUTICS INC | Kary Eldred director | $2,611 700 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.